Search - tctmd.com

Displaying 481 - 500 of 671

Sort: Relevancy | Date

News Daily News

Nationwide Registry Shows Trends in DES Use Over a Decade

June 02, 2014

News Conference News EuroPCR 2014

EuroPCR Features PAD Therapies in Early Development and Real-World Use

Caitlin E. Cox

May 21, 2014

News Daily News

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

May 20, 2014

News Daily News

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

May 20, 2014

News Conference News EuroPCR 2014

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

Caitlin E. Cox

May 20, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

News Daily News

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

April 30, 2014

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

Presentation Fellows 2014

Stent Thrombosis and Restenosis

Presenter: Ajay Kirtane

April 13, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

Presentation Physiology and Intravascular Imaging 2014

Mechanisms and Predictors of In-stent Restenosis and Stent Thrombosis

Presenter: Soo-Jin Kang

March 27, 2014

Presentation

Lack of Association Between DAPT Use and Stent Thrombosis Between 1 and 12 Months Following Resolute ZES Implantation

Presenter: 115704|Sigmund Silber

February 17, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Daily News

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

February 12, 2014

News Daily News

Stent Malapposition Frequent, But Without Clinical Consequences

Jason Kahn

January 27, 2014

News Daily News

La Mala Aposición del Stent es algo Frecuente que No tiene Consecuencias Clínicas

Jason Kahn

January 27, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

Los SLF de 1ª Generación son Menos Rentables que SMD + Rapamicina Oral a los 5 Años

January 06, 2014

Advertisement

Nationwide Registry Shows Trends in DES Use Over a Decade

EuroPCR Features PAD Therapies in Early Development and Real-World Use

Short-term DAPT After DES Decreases Bleeding with No Increase in Death, MI

La Terapia Antiplaquetaria Doble a Corto Plazo Post-Implantación de SLF Reduce las Hemorragias Sin un Aumento de Muerte ni IM

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Long-term Outcomes of ‘Full Metal Jacket’ Stenting Appear Favorable

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Stent Thrombosis and Restenosis

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Mechanisms and Predictors of In-stent Restenosis and Stent Thrombosis

Lack of Association Between DAPT Use and Stent Thrombosis Between 1 and 12 Months Following Resolute ZES Implantation

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

Stent Malapposition Frequent, But Without Clinical Consequences

La Mala Aposición del Stent es algo Frecuente que No tiene Consecuencias Clínicas

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Los SLF de 1ª Generación son Menos Rentables que SMD + Rapamicina Oral a los 5 Años

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content